1. Home
  2. PSO vs PTGX Comparison

PSO vs PTGX Comparison

Compare PSO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

N/A

Current Price

$15.98

Market Cap

9.8B

ML Signal

N/A

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

N/A

Current Price

$145.44

Market Cap

9.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSO
PTGX
Founded
1844
2006
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
9.3B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
PSO
PTGX
Price
$15.98
$145.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
13
Target Price
N/A
$108.23
AVG Volume (30 Days)
543.5K
437.4K
Earning Date
02-27-2026
05-07-2026
Dividend Yield
2.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.35
Revenue
N/A
N/A
Revenue This Year
$5.26
$874.25
Revenue Next Year
$4.54
N/A
P/E Ratio
$14.05
$63.18
Revenue Growth
N/A
N/A
52 Week Low
$12.02
$57.90
52 Week High
$17.75
$160.81

Technical Indicators

Market Signals
Indicator
PSO
PTGX
Relative Strength Index (RSI) 44.30 53.39
Support Level $15.94 $127.98
Resistance Level $17.70 $160.81
Average True Range (ATR) 0.23 5.71
MACD -0.02 -1.52
Stochastic Oscillator 22.62 34.55

Price Performance

Historical Comparison
PSO
PTGX

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualifications, testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and the publishing house Penguin, and is now focused on serving as an educational resource and testing provider.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: